191 related articles for article (PubMed ID: 19563872)
1. In vitro and in vivo antitumor activity of oridonin nanosuspension.
Lou H; Zhang X; Gao L; Feng F; Wang J; Wei X; Yu Z; Zhang D; Zhang Q
Int J Pharm; 2009 Sep; 379(1):181-6. PubMed ID: 19563872
[TBL] [Abstract][Full Text] [Related]
2. Oridonin nanosuspension enhances anti-tumor efficacy in SMMC-7721 cells and H22 tumor bearing mice.
Lou H; Gao L; Wei X; Zhang Z; Zheng D; Zhang D; Zhang X; Li Y; Zhang Q
Colloids Surf B Biointerfaces; 2011 Oct; 87(2):319-25. PubMed ID: 21676599
[TBL] [Abstract][Full Text] [Related]
3. Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by oridonin nanosuspension.
Feng FF; Zhang DR; Tian KL; Lou HY; Qi XL; Wang YC; Duan CX; Jia LJ; Wang FH; Liu Y; Zhang Q
Drug Deliv; 2011 May; 18(4):265-71. PubMed ID: 21091387
[TBL] [Abstract][Full Text] [Related]
4. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions.
Gao L; Zhang D; Chen M; Duan C; Dai W; Jia L; Zhao W
Int J Pharm; 2008 May; 355(1-2):321-7. PubMed ID: 18242896
[TBL] [Abstract][Full Text] [Related]
5. In vitro antitumor activity of silybin nanosuspension in PC-3 cells.
Zheng D; Wang Y; Zhang D; Liu Z; Duan C; Jia L; Wang F; Liu Y; Liu G; Hao L; Zhang Q
Cancer Lett; 2011 Aug; 307(2):158-64. PubMed ID: 21507570
[TBL] [Abstract][Full Text] [Related]
6. Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies.
Wang S; Chen T; Chen R; Hu Y; Chen M; Wang Y
Int J Pharm; 2012 Jul; 430(1-2):238-46. PubMed ID: 22465546
[TBL] [Abstract][Full Text] [Related]
7. Oridonin-loaded poly(epsilon-caprolactone)-poly(ethylene oxide)-poly(epsilon-caprolactone) copolymer nanoparticles: preparation, characterization, and antitumor activity on mice with transplanted hepatoma.
Feng N; Wu P; Li Q; Mei Y; Shi S; Yu J; Xu J; Liu Y; Wang Y
J Drug Target; 2008 Jul; 16(6):479-85. PubMed ID: 18604660
[TBL] [Abstract][Full Text] [Related]
8. An HPLC method for determination of oridonin in rabbits using isopsoralen as an internal standard and its application to pharmacokinetic studies for oridonin-loaded nanoparticles.
Mei Y; Xu J; Zhao J; Feng N; Liu Y; Wei L
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jun; 869(1-2):138-41. PubMed ID: 18514594
[TBL] [Abstract][Full Text] [Related]
9. In vivo studies on the oridonin-loaded nanostructured lipid carriers.
Zheng D; Dai W; Zhang D; Duan C; Jia L; Liu Y; Zhang Q
Drug Deliv; 2012 Aug; 19(6):286-91. PubMed ID: 22928767
[TBL] [Abstract][Full Text] [Related]
10. [Regulation of telomerase activity and cell cycle of K562 cells by oridonin].
Li RF; Wang QD
Yao Xue Xue Bao; 2004 Nov; 39(11):865-8. PubMed ID: 15696923
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effect of oridonin and cisplatin on cytotoxicity and DNA cross-link against mouse sarcoma S180 cells in culture.
Gao ZG; Ye QX; Zhang TM
Zhongguo Yao Li Xue Bao; 1993 Nov; 14(6):561-4. PubMed ID: 8010060
[TBL] [Abstract][Full Text] [Related]
12. Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement.
Gao L; Zhang D; Chen M; Zheng T; Wang S
Drug Dev Ind Pharm; 2007 Dec; 33(12):1332-9. PubMed ID: 18097807
[TBL] [Abstract][Full Text] [Related]
13. Galactosylated chitosan nanoparticles for hepatocyte-targeted delivery of oridonin.
Zheng D; Duan C; Zhang D; Jia L; Liu G; Liu Y; Wang F; Li C; Guo H; Zhang Q
Int J Pharm; 2012 Oct; 436(1-2):379-86. PubMed ID: 22732673
[TBL] [Abstract][Full Text] [Related]
14. The anti-tumor effect of folate-targeted liposome microbubbles loaded with oridonin as ultrasound-triggered tumor-targeted therapeutic carrier system.
Wang C; Li W; Hu B
J Drug Target; 2017 Jan; 25(1):83-91. PubMed ID: 27282800
[TBL] [Abstract][Full Text] [Related]
15. Effects of oridonin nanosuspension on cell proliferation and apoptosis of human prostatic carcinoma PC-3 cell line.
Zhang Z; Zhang X; Xue W; Yangyang Y; Xu D; Zhao Y; Lou H
Int J Nanomedicine; 2010 Oct; 5():735-42. PubMed ID: 21042419
[TBL] [Abstract][Full Text] [Related]
16. Actinomycin D inhibiting K562 cell apoptosis elicited by salvicine but not decreasing its cytotoxicity.
Qing C; Miao ZH; Tong LJ; Zhang JS; Ding J
Acta Pharmacol Sin; 2003 May; 24(5):415-21. PubMed ID: 12740176
[TBL] [Abstract][Full Text] [Related]
17. [The tissue distribution in mice and pharmacokinetics in rabbits of oridonin-solid lipid nanoparticles].
Zhang DR; Ren TC; Lou HX; Xing J
Yao Xue Xue Bao; 2005 Jun; 40(6):573-6. PubMed ID: 16144328
[TBL] [Abstract][Full Text] [Related]
18. Oridonin inhibits the proliferation of human osteosarcoma cells by suppressing Wnt/β-catenin signaling.
Liu Y; Liu YZ; Zhang RX; Wang X; Meng ZJ; Huang J; Wu K; Luo JY; Zuo GW; Chen L; Yin LJ; Deng ZL; He BC
Int J Oncol; 2014 Aug; 45(2):795-803. PubMed ID: 24859848
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo anticancer activity of a novel puerarin nanosuspension against colon cancer, with high efficacy and low toxicity.
Wang Y; Ma Y; Zheng Y; Song J; Yang X; Bi C; Zhang D; Zhang Q
Int J Pharm; 2013 Jan; 441(1-2):728-35. PubMed ID: 23089583
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of AP-1 gene expression is an initial event in the oridonin-mediated inhibition of colorectal cancer: studies in vitro and in vivo.
Jin H; Tan X; Liu X; Ding Y
J Gastroenterol Hepatol; 2011 Apr; 26(4):706-15. PubMed ID: 21418301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
